Edition:
United States

Biotechnology & Medical Research

Page 1

Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

Friday, 29 Jul 2016 09:40am EDT

: Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: [MDVN.O] (Bengaluru Newsroom: +1 646 223 8780).

Ligand announces licensing agreement with Nucorion Pharmaceuticals

Friday, 29 Jul 2016 08:30am EDT

Ligand Pharmaceuticals Inc : Ligand announces multi-program LTP technology licensing agreement with nucorion pharmaceuticals . Newly-Formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets . Eligible to receive milestone payments as well as royalties ranging from 5% to 9% on net sales of products developed by Nucorion under agreement .Ligand announces multi-program LTP technology licensing agreement with Nucorion pharmaceuticals.

Jazz Pharmaceuticals and Pfenex enter into an agreement

Thursday, 28 Jul 2016 04:05pm EDT

Pfenex Inc : Under agreement, Pfenex will receive upfront and option payments totaling $15 million . Co may be eligible to receive additional payments of up to $166 million based on achievement of certain development milestones . Pfenex may also be eligible to receive tiered royalties on worldwide sales of any products resulting from collaboration .Jazz Pharmaceuticals and Pfenex enter into a worldwide license and option agreement related to product candidates in early development for Hematological Malignancies.

Sun Pharma and Almirall signs license deal for Psoriasis treatment

Wednesday, 27 Jul 2016 10:32pm EDT

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .

China Regenerative Medicine unit enters into loan agreement<8158.HK>

Tuesday, 26 Jul 2016 12:14am EDT

China Regenerative Medicine International Ltd <8158.HK>: Discloseable transaction provision of the loan to an independent third party . Unit entered into a loan agreement with the borrower . Deal for HK$50 million . Borrower an independent third party incorporated in the British Virgin Islands .

Race Oncology signs agreement with camargo pharmaceutical

Monday, 25 Jul 2016 07:21pm EDT

Race Oncology Ltd : Signs agreement with camargo pharmaceutical . Says camargo will assemble a technical dossier on bisantrene, prepare and submit a pre-ind meeting request with the FDA . Says project is expected to take approximately six months .

Bind Therapeutics says two bidders join Pfizer's stalking horse bid

Monday, 25 Jul 2016 07:00am EDT

Bind Therapeutics Inc : Bids are in addition to pfizer inc.'s initial stalking horse bid of approximately $20 million under section 363 of u.s. Bankruptcy code . Bind therapeutics announces two bidders join pfizer's stalking horse bid in auction for bind's assets . u.s. Bankruptcy court has authorized bind to proceed with an auction on july 25, 2016 .Winning bid is subject to u.s. Bankruptcy court approval and a hearing is scheduled to take place on july 27, 2016.

Relypsa to pay $49 mln to Galenica AG if deal called off

Thursday, 21 Jul 2016 08:33am EDT

Relypsa Inc :Co to pay Galenica AG termination fee of $49 million in cash if deal is terminated.

Starpharma signs exclusive license and supply agreement in China

Wednesday, 20 Jul 2016 11:10pm EDT

Starpharma Holdings Ltd : Signs exclusive license and supply agreement with Shenyang sky and land latex for manufacture and sale of vivagel condoms .

Hansa Medical acquires UK-based Immago Biosystems Ltd

Tuesday, 19 Jul 2016 07:00am EDT

Hansa Medical AB : Acquires United Kingdom based Immago Biosystems Ltd . Acquisition will not have a significant impact on Hansa Medical result for 2016 . Sum of acquisition was not disclosed .Immago Biosystems Ltd is a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.